Inclusion Criteria:

- Willing and able to understand and sign an informed consent form (ICF) for the study
approved by the Investigator's local or a central Institutional Review Board (IRB)

- Have recently diagnosed, pathologically confirmed, non-metastatic SCC of the oral
cavity, oropharynx, hypopharynx, or larynx that will be treated with ChemoRT as
first-line treatment; subjects with a history of surgical management are eligible

- Have a plan to receive a continuous course of conventional external beam irradiation
delivered by intensity-modulated radiotherapy (IMRT) as single daily fractions of 2.0
to 2.2 Gy, with a cumulative radiation dose between 50 and 72 Gy. Planned radiation
treatment fields must include at least 2 oral sites (buccal mucosa, floor of oral
cavity, tongue, or soft palate), with each site receiving ≥ 50 Gy

- Have a plan to receive a standard cisplatin CT regimen administered tri-weekly (80 to
100 mg/m2, on Days 0, 21, and 42) or weekly (30 to 40 mg/m2)

- Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

- Have adequate hematopoietic, hepatic, and renal function at the screening visit:

- Hematopoietic function

- Hemoglobin ≥ 10 g/dL

- Absolute neutrophil counts (ANC) ≥ 1,500 cells/mm3

- Platelet count ≥ 100 × 109/L

- Hepatic function

- Total bilirubin < 1.5 times the upper-normal limit (ULN)

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.0
times the ULN

- Renal function: Serum creatinine concentration ≤ 2 mg/dL; if result is ≥ 1.4
mg/dL and ≤ 2.0 mg/dL, a 24-hour urinary creatinine clearance test must be
performed by the site's local laboratory. To be eligible for the study, a
subject must demonstrate a 24-hour urinary creatinine clearance ≥ 50 mL/min

- Have a negative serum pregnancy test if a woman is of childbearing potential

- Agree to use medically acceptable methods of birth control during study participation
and for 30 days following the last CTM treatment if a woman is of childbearing
potential

- Males or females aged 18 years or older.

Exclusion Criteria:

- Tumor of the lips, sinuses, salivary glands, nasopharynx, or unknown primary tumor

- Metastatic disease (M1) Stage IV C

- Prior radiation to the head and neck

- Plan to be treated with cetuximab (Erbitux®)

- Have undergone induction CT

- History of other malignant tumors, excluding non-melanoma skin cancer or curatively
excised in situ cervical carcinoma

- Have had a major surgical procedure, other than for HNC, or significant traumatic
injury within 4 weeks prior to the initiation of RT; anticipation of need for a major
surgical procedure during the study

- Active infectious disease, excluding oral candidiasis

- Have OM at the baseline visit

- Have a diagnosis of autoimmune disease requiring chronic immunosuppression

- Known seropositivity for HIV, HBV, or HCV

- Prior use of SCV 07

- Have used any investigational agent within 30 days of randomization

- Are pregnant or breastfeeding

- Known allergies or intolerance to cisplatin

- Unable to give informed consent or comply with study requirements, including
completing the subject diary and QOL instruments

- Have any other condition or therapy that, in the opinion of the Investigator, would
make the subject unsuitable for the study or unable to comply with follow-up visits.